Latisse hair growth trials

The study, based out of Tempe, Arizona, will test two different formulations of bimatoprost in men who suffer from moderate male pattern baldness and women who have moderate female patterned alopecia. The completion date of the study is February , so we will look for the results and share them with you when they are available.

The results of the study have been published and it did not result in the FDA approving Latisse for hair loss on the scalp. See the results of the study on ClinicalTrials. It is currently being studied at several academic centers and may be commercially available in ten years.

My hair feels like it doubles in size after each use. Wish me luck. Alan Bauman, a hair-restoration specialist based in Florida who helped pioneer the use of bimatoprost in his hair loss patients. Jerry Shapiro of the New York University Langone Medical Center told ABC News in May that although the Food and Drug Administration has approved Latisse only for eyelashes and it is not the first line of treatment for hair loss on the scalp or eyebrows, it may help patients who are not getting the desired results from other treatments 3 5.

In fact, Allergan, the manufacturer of Latisse is conducting clinical trials and safety tests required for an FDA approval, which will lead to wider use of the product 3. Latisse may cause hyperpigmentation of the skin with prolonged contact 3. This can lead to unwanted dark spots on your skin. Also, eyelash growth returns to pretreatment level upon discontinuation, according to Drugs. Discuss the potential benefits and side effects of Latisse with your doctor before starting the treatment 3.

Inform your doctor of any pre-existing conditions or other medication you might be taking. Latisse has not been approved for children 3. FDA Resources.

Arms and Interventions. During Part I of the study, subjects will be randomized in a blinded fashion to either placebo vehicle that does not contain active drug or topical bimatoprost to apply to the scalp target area every day for 16 weeks. Outcome Measures. Primary Outcome Measures : Percent Change in Target Area Total Hair Count [ Time Frame: Baseline to week 17; and week 17 to week 34 ] The primary endpoint is the percent change in total hair count from the beginning and end of each part of the study.

Vellus hairs are fine hairs that generally do not grow beyond 1 cm and do not contribute to overall hair density. They are increased in number in male pattern baldness. The percent change in hair diameter is a recent addition to the methods of assessing efficacy of hair growth promoters. Eligibility Criteria. Information from the National Library of Medicine Choosing to participate in a study is an important personal decision.

Subject's hair color must have adequate contrast against scalp color to allow hair counting on macrophotography. Good health with normal blood tests for hematological, renal, and liver function. Able to return to Duke for study visits.

Used topical or oral minoxidil in the past 6 months, oral finasteride in the past 12 months or oral dutasteride in the past 24 months. Taken any warfarin, heparin, or retinoid for greater than 2 weeks during the past 6 months and any in the past month. Taken any chemotherapy in the past 2 years. Used any over-the-counter OTC preparation that purports to help hair growth in the past four months.